EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation

Zoe Lombardi, Lucia Gardini, Anatolii V Kashchuk, Alessio Menconi, Matteo Lulli, Ignazia Tusa, Alessandro Tubita, Luisa Maresca, Barbara Stecca, Marco Capitanio, Elisabetta Rovida iD

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.13674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Zoe Lombardi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Biomedical Sciences, University of Florence, Italy. Hauptthemen laut MEDLINE: beta Karyopherins, Cell Proliferation, Mitogen-Activated Protein Kinase 7, Cell Nucleus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Ministero dell'Istruzione, dell'Università e della Ricerca, European Union Horizon 2020 Research and Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mitogen‐activated protein kinase (MAPK) extracellular signal‐regulated kinase 5 (ERK5) is emerging as a promising target in cancer. Indeed, alterations of the MEK5/ERK5 pathway are present in many types of cancer, including melanoma. One of the key events in MAPK signalling is MAPK nuclear translocation and its subsequent regulation of gene expression. Likewise, the effects of ERK5 in supporting cancer cell proliferation have been linked to its nuclear localization. Despite many processes regulating ERK5 nuclear translocation having been determined, the nuclear transporters involved have not yet been identified. Here, we investigated the role of importin subunit alpha (α importin) and importin subunit beta‐1 (importin β1) in ERK5 nuclear shuttling to identify additional targets for cancer treatment. Either importin β1 knockdown or the α/β1 importin inhibitor ivermectin reduced the nuclear amount of overexpressed and endogenous ERK5 in HEK293T and A375 melanoma cells, respectively. These results were confirmed in single‐molecule microscopy in HeLa cells. Moreover, immunofluorescence analysis showed that ivermectin impairs epidermal growth factor (EGF)‐induced ERK5 nuclear shuttling in HeLa cells. Both co‐immunoprecipitation experiments and proximity ligation assay provided evidence that ERK5 and importin β1 interact and that this interaction is further induced by EGF administration and prevented by ivermectin treatment. The combination of ivermectin and the ERK5 inhibitor AX15836 synergistically reduced cell viability and colony formation ability in A375 and HeLa cells and was more effective than single treatments in preventing the growth of A375 and HeLa spheroids. The increased reduction of cell viability upon the same combination was also observed in patient‐derived metastatic melanoma cells. The combination of ivermectin and ERK5 inhibitors other than AX15836 provided similar effects on cell viability. The identification of importin β1 as the nuclear transporter of ERK5 may be exploited for additional ERK5‐inhibiting strategies for cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta KaryopherinsCell ProliferationMitogen-Activated Protein Kinase 7Cell NucleusProtein Kinase InhibitorsHumansHeLa CellsHEK293 CellsActive Transport, Cell NucleusIvermectinDrug SynergismMelanomaCell Line, Tumor

Stichwörter der Autor:innen

KPNB1MAPK7combined therapyivermectinnuclear import

Substanzen

beta KaryopherinsMitogen-Activated Protein Kinase 7Protein Kinase InhibitorsKPNB1 protein, humanMAPK7 protein, humanIvermectin

Autor:innen und Institutionen

  • Department of Clinical and Experimental Biomedical Sciences, University of Florence, Italy.
  • National Institute of Optics, National Research Council, Florence, Italy.
  • European Laboratory of Non-Linear Spectroscopy (LENS), Florence, Italy.
  • Department of Physics and Astronomy, University of Florence, Italy.
  • Core Research Laboratory - Institute for Cancer Research and Prevention (ISPRO), Florence, Italy.

ORCID-Profile: Elisabetta Rovida

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • European Union Horizon 2020 Research and Innovation Program
  • Fondazione Cassa di Risparmio di Firenze
  • European Union
  • Fondazione AIRC per la ricerca sul cancro ETS
  • European Commission

Zitieren

APA

Lombardi, Z., Gardini, L., Kashchuk, A. V., Menconi, A., Lulli, M., Tusa, I., Tubita, A., Maresca, L., Stecca, B., Capitanio, M., & Rovida, E. (2025). Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation. Molecular Oncology. https://doi.org/10.1002/1878-0261.13674

Vancouver

Lombardi Z, Gardini L, Kashchuk AV, Menconi A, Lulli M, Tusa I, et al. Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation. Molecular Oncology. 2025. doi:10.1002/1878-0261.13674

BibTeX
@article{Lombardi2025,
  author = {Lombardi, Zoe and Gardini, Lucia and Kashchuk, Anatolii V and Menconi, Alessio and Lulli, Matteo and Tusa, Ignazia and Tubita, Alessandro and Maresca, Luisa and Stecca, Barbara and Capitanio, Marco and Rovida, Elisabetta},
  title = {Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.13674}
}
Kostenlos starten →